IRIS

Carbon tetrachloride

CASRN 56-23-5 | DTXSID8020250

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (20 pp, 363 K) Last Updated: 03/31/2010

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic 4 x 10 -3 Elevated serum SDH activity BMDL 2x (ADJ): 3.9
mg/kg-day
1000 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (20 pp, 363 K) Last Updated: 03/31/2010

System RfC (mg/m3) Basis PoD Composite UF Confidence
Hepatic 1 x 10 -1 Fatty changes in the liver BMCL 10 (HEC): 14.3
mg/m3
100 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (20 pp, 363 K) Last Updated: 03/31/2010

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), carbon tetrachloride is "likely to be carcinogenic to humans."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (20 pp, 363 K)

Oral Slope Factor: 7 x 10-2 per mg/kg-day
Drinking Water Unit Risk: 2 x 10-6 per µg/L
Extrapolation Method: Multistage model with linear extrapolation from the POD (LED10).
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenoma or carcinoma (Nagano et al., 2007b, JBRC, 1998)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (20 pp, 363 K)

Inhalation Unit Risk: 6 x 10-6 per µg/m3
Extrapolation Method: Log-probit model with linear extrapolation from the POD (LEC10).
Tumor site(s): Endocrine
Tumor type(s): Pheochromocytoma (Nagano et al. 2007b, JBRC 1998)

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.